Slavin S - Search Results

1

Activated long-term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients.

Morecki S, Gelfand Y, Levi S, Nagler A, Condiotti R, Nabet C, Ackerstein A, Slavin S. Morecki S, et al. Among authors: slavin s. J Hematother. 1997 Apr;6(2):115-24. doi: 10.1089/scd.1.1997.6.115. J Hematother. 1997. PMID: 9131440

2

Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a.

Nagler A, Ackerstein A, Barak V, Slavin S. Nagler A, et al. Among authors: slavin s. J Hematother. 1994 Spring;3(1):75-82. doi: 10.1089/scd.1.1994.3.75. J Hematother. 1994. PMID: 7922012 Clinical Trial.

3

Effect of various cytokine combinations on induction of non-MHC-restricted cytotoxicity.

Morecki S, Nagler A, Puyesky Y, Nabet C, Condiotti R, Pick M, Gan S, Slavin S. Morecki S, et al. Among authors: slavin s. Lymphokine Cytokine Res. 1993 Jun;12(3):159-65. Lymphokine Cytokine Res. 1993. PMID: 8347764

4

Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.

Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R. Slavin S, et al. Blood. 1996 Mar 15;87(6):2195-204. Blood. 1996. PMID: 8630379 Free article.

5

The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors.

Condiotti R, Slavin S, Barak V, Nagler A. Condiotti R, et al. Among authors: slavin s. Leuk Res. 1996 Jan;20(1):57-63. doi: 10.1016/0145-2126(95)00110-7. Leuk Res. 1996. PMID: 8632678

6

Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.

Kapelushnik J, Nagler A, Or R, Naparstek E, Ackerstein A, Samuel S, Morecki S, Nabet C, Slavin S. Kapelushnik J, et al. Among authors: slavin s. Bone Marrow Transplant. 1996 Dec;18(6):1153-6. Bone Marrow Transplant. 1996. PMID: 8971387

7

Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.

Vourka-Karussis U, Ackerstein A, Pugatsch T, Slavin S. Vourka-Karussis U, et al. Among authors: slavin s. Exp Hematol. 1999 Mar;27(3):461-9. doi: 10.1016/s0301-472x(98)00026-5. Exp Hematol. 1999. PMID: 10089908 Free article.

8

Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease.

Morecki S, Slavin S. Morecki S, et al. Among authors: slavin s. J Hematother Stem Cell Res. 2000 Jun;9(3):355-66. doi: 10.1089/15258160050079461. J Hematother Stem Cell Res. 2000. PMID: 10894357 Review. No abstract available.

9

Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation.

Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S. Nagler A, et al. Among authors: slavin s. Exp Hematol. 2000 Nov;28(11):1225-31. doi: 10.1016/s0301-472x(00)00533-6. Exp Hematol. 2000. PMID: 11063870 Free article.

10

Combination of magnetic and chemocytotoxic cancer cell depletion for autologous bone marrow transplantation.

Morecki S, Slavin S. Morecki S, et al. Among authors: slavin s. Isr J Med Sci. 1988 Sep-Oct;24(9-10):488-93. Isr J Med Sci. 1988. PMID: 3060442

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

770 results

Search Page

Filters